AVALIAÇÃO DOS EFEITOS DE UM LIPÍDIO RESORCINÓLICO E DE UMA NORCANTARIMIDA SOBRE O DNA E SUAS INTERFERÊNCIAS NA AÇÃO DE QUIMIOTERÁPICOS COMERCIAIS

Abstract

Cancer stands as the main cause of mortality, with over 19.3 million new cases, posing a hindrance to the global increase in life expectancy. These numbers demonstrate that, despite clinical efforts, treatments do not achieve the desired success. Considering the increasing incidence of new cases and the high costs associated of treating this disease, it is important to emphasize the need for the exploration of novel molecules and to understand the effects of associated therapies to determine potential synergistic, additive, or antagonistic effects. This knowledge may determine the development of new complementary or adjunctive therapies and/or contraindicate the combination of compounds/medications. Hence, this study aimed to assess the effects of a resorcinolic lipid and a norcantharimide on DNA and their interference with the action of commercial chemotherapy drugs. ZIM induces genomic and chromosomal damage, activates splenic phagocytosis, and increases the frequency of cell death in the liver and kidneys. Conversely, Phthalide exhibits genotoxicity by increasing micronucleus frequencies. Additionally, it activates splenic phagocytosis and elevates the frequency of cell death in the liver and kidneys. When combined, ZIM demonstrates chemopreventive effects and interferes with the mechanisms of cisplatin, doxorubicin, and cyclophosphamide. Phthalide, on the other hand, can be considered a chemotherapeutic adjuvant as it potentiates the effects of cisplatin and cyclophosphamide. Based on these results, it can be inferred that ZIM and Phthalide hold clinical applicability and may serve as candidates for the development of a new generation of chemotherapeutic agents.